Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Intellia Therapeutics, Inc. logoIntellia Therapeutics, Inc.

NTLA · Nasdaq · USD · Market cap $1.4B · 377 employees

Intellia Therapeutics, Inc.

FAIL · Does not pass the screen
10.00 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price10.00 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 1.93)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $8.00 to $19.54, base estimate $15.50 (screen dated 2026-11-20).

Current read
Distribution ?
Undervalued · screened 2026-11-20
  • Trend Distribution
  • Insiders insiders sold, $23,170, latest filing 2026-10-02
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.93, read 2026-11-18
  • Ethical does not pass the values gate
Price10.00 USD
Fair value15.50
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-05Read Distribution12.31-18.8% to today ✓Accumulation gives way to Distribution
2026-11-01Read Accumulation12.47-19.8% to today Markdown gives way to Accumulation after a 9% rise in 2 weeks
2026-10-18Read Markdown11.43-12.5% to today ✓Accumulation gives way to Markdown after an 8% slide in 7 days
2026-10-11Read Accumulation12.37-19.2% to today Markdown gives way to Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Intellia Therapeutics, Inc. holds its Distribution at $10.00. Consolidating, no directional conviction, held for 208 days.

As held on the ledger · 2026-11-20
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 208 days
Price at the screen$10.00
ValuationN/A trailing · -3.63 forward price to earnings
Values screenFAIL · score 70.0
Beta1.82
The Workings

Five Screens: NTLA's Results

FAIL. Revenue purity

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 11.08% Below 33% Pass
Interest-bearing cash 18.44% Below 33% Pass
Receivables 19.59% Below 49% Pass
Revenue purity 43.14% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Intellia Therapeutics, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 43% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when NTLA's ethical verdict changes

Today NTLA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 35% discount to our $15.50 fair value.

Method.

8.00Conservative15.50Base case19.54Growth case 10.00Price

USD, 2026-11-20 screen. A 35.5% under base.

The Street's Range
8.00Street low 15.50Street average 61.00Street high 10.00Price

Street: 18 covering, consensus Buy. Average target +55%.

Chart
The Business, in Plain Words

CRISPR dreams meet clinical stage reality

Picture a lab bench where gene edits could one day fix rare diseases at source. Intellia is still years from that payoff, burning cash on early trials while revenue slipped 10 percent last year and margins sit at zero.

We pass despite the 58 percent gap to our own fair value and a clean ethical screen. Forward earnings sit at negative 6.5 times, return on equity is minus 56 percent, and the business has yet to prove it can scale beyond the lab. Analyst targets cluster at the same $18 level, yet none of that changes the absence of profits or a visible moat.

Clinical setbacks, regulatory delays and repeated equity raises remain the real story here. A single failed study can wipe out years of progress, and negative cash flow offers little cushion when funding markets turn cold. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-3.6x
EPS, trailing-3.35
EPS, forward-2.70
Revenue growth-48.0%revenue is shrinking
Profit margin0.0%currently unprofitable
Return on equity-62.6%not currently earning a positive return on equity
FCF yield-12.18%
Debt to equity0.38minimal debt: a conservative balance sheet
Current ratio6.31comfortably covers its short-term bills
Beta1.82much more volatile than the market
Short interest, float0.40%
52-week range7.95 - 18.48
Market cap$1.4B
Employees377

NTLA-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Distribution $9.77 +0.0% Entry 20
2026-11-19 Distribution $9.77 -14.4% Entry 19
2026-11-12 Distribution $11.41 -7.3% Entry 18
2026-11-05 Distribution · changed $12.31 +3.8% Entry 17

The framework has shifted from accumulation to distribution since the last review.

2026-11-04 Accumulation $11.86 -4.9% Entry 16
2026-11-03 Accumulation $12.47 +0.0% Entry 15
2026-11-02 Accumulation $12.47 +0.0% Entry 14
2026-11-01 Accumulation · changed $12.47 +11.2% Entry 13

The framework has shifted from markdown to accumulation since the last review.

2026-10-31 Markdown $11.21 +0.0% Entry 12
2026-10-30 Markdown $11.21 +0.0% Entry 11

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on NTLA

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in NTLA's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · NTLA
DateInsiderTitleTypeSharesValue
2026-10-02 Dube Michael P VP, Chief Accounting Officer S - Sale 1,864 $23,170

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $14.42 -14.2% · $858 -14.2%
2 months $13.49 -8.3% · $917 -8.3%
3 months $12.85 -3.7% · $963 -3.7%
6 months $9.55 +29.6% · $1,296 +29.6%
1 year $8.47 +46.1% · $1,461 +46.1%
2 years $23.28 -46.8% · $532 -46.8%
3 years $43.24 -71.4% · $286 -71.4%
5 years $85.29 -85.5% · $145 -85.5%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever NTLA does next, these words stay.

Intellia Therapeutics, Inc. · NTLA · Distribution · $10.00
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.